Wockhardt has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations as well as Active Pharmaceutical Ingredients (API).
The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 14 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe.
The state-of-the-art biotech plant in Aurangabad has six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. The Wockhardt Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology.
Strengthening our core capabilityWockhardt’s success in building an international manufacturing footprint has earned it the reputation of a world-class manufacturer.It has invested heavily in recent years in technologically advanced manufacturing plants, ensuring their compliance with US and European regulatory requirements.
As the demand for contract manufacturing grows, Wockhardt continues to upgrade its world-class facilities and make further investments in new units and processes. The state-of-the-art lyophilisation unit at Shendra, Aurangabad in India, is a first of its kind in Asia. The plant is fully automated to provide high quality injectable products. Another plant at Aurangabad includes the manufacture of nano-particles for all dosage forms to meet the latest advanced technology.
Finished Dosage Manufacturing - India
Finished Dosage Manufacturing - International